^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy
Published date:
06/06/2020
Excerpt:
Retrospective analysis was performed on the clinical and sequencing data obtained from eleven patients with lung adenocarcinoma who acquired MET amplification....Acquired MET amplification was detected in four and seven patients who progressed from first-line gefitinib and second-line osimertinib, respectively. Six and five patients received a combination of either first-generation (gefitinib, erlotinib, or icotinib) or third-generation (osimertinib) EGFR-TKI and crizotinib, respectively. Nine patients achieved partial response, resulting in an overall response rate of 81.8 %. The median progression-free survival of the cohort was 5.8 months.
DOI:
10.1016/j.lungcan.2020.06.003
Source:
Title:
TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
Published date:
03/09/2020
Excerpt:
NGS showed EGFR exon21 L858R mutation with newly emerged MET amplification and TPD52L1-ROS1 rearrangement...the patient received the treatment of crizotinib combined with osimertinib…which was found to be effective with substantial decrease of pleural effusion and disappearance of lymph node in the right axilla in two months.
DOI:
https://doi.org/10.1016/j.jtocrr.2020.100034
